{
  "docId": "019de074-d961-7389-a20b-cd17e719b042",
  "docSlug": "eb72a4aa6f7d8bed68bc577a406605bf",
  "documentTitle": "BioAtla | Investor Presentation Deck | 44 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 44,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Uses a 2x2 grid layout to present key epidemiological and clinical data points.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-d961-7389-a20b-cd17e719b042/28",
  "deckHref": "/decks/019de074-d961-7389-a20b-cd17e719b042",
  "deckJsonHref": "/decks/019de074-d961-7389-a20b-cd17e719b042.json",
  "deckAnchorHref": "/decks/019de074-d961-7389-a20b-cd17e719b042#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.03,
        "y": 0.76
      },
      "kind": "list",
      "text": "Target population: ~5K ROR2+ addressable 2L+ patients/year in the U.S., based on a ROR2 positivity rate of ~10%. Internal success threshold: 2L+ ORR of ~20% (approvability bar based on precedent); 25%+ (commercially relevant) following BA3011 monotherapy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3eeed843-cfd6-4950-b37f-f0c6ab0742c0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.03,
        "y": 0.45
      },
      "kind": "metric",
      "text": "~50% do not respond to PD-1 therapy in 1L setting",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e833b01-35e1-4f34-bbf0-331ac56ada4c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.35,
        "y": 0.45
      },
      "kind": "metric",
      "text": "30-40% initial responders progress",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a139021-bfc1-42c2-8451-49da7b81553d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.35,
        "y": 0.195
      },
      "kind": "metric",
      "text": "~100K newly diagnosed invasive cases / year (U.S.)",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d3ac0c3-0313-4cb4-96f5-40d58e152a2a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.03,
        "y": 0.195
      },
      "kind": "metric",
      "text": "~1.3MM people in the U.S. living with melanoma",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79ad345d-a99e-46a8-b776-58398d96415b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.7,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Available Treatment: 1L: ICIs 33% - 50% ORR; (BRAF / Mek inhibitors for BRAF+). 2L+: ICIs 9% - 28% ORR (mono – combo, respectively)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe54ddb6-7de5-4cf9-8914-43fc32eba96b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.11,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Clarivate, Disease Landscape and Forecast: Malignant Melanoma (2022)...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a52d2156-47aa-4c91-b8f2-4d440bbfa33a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Potential market opportunity in metastatic melanoma",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b20df4f0-d2b2-445f-95ed-b29477df4c25",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}